Spectrum Pharmaceuticals, Inc.

Release Summary

Spectrum Pharmaceuticals Announces Detailed Results from Phase 3 Study of ROLONTIS® (eflapegrastim) Published in an ASCO Abstract

Spectrum Pharmaceuticals, Inc.